Oncolytics presents positive updated Phase 1/2 pancreatic cancer data

Oncolytics announced the poster presentation of positive, updated results from the Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma at the European Society for Medical Oncology meeting in Madrid, Spain. “We are very pleased to share such positive and consistent data on pelareorep from the PDAC arm of the GOBLET study, including an impressive overall response rate, 7.2 months of median progression-free survival, interim median overall survival of 10.6 months, and expansion of both pre-existing and new T-cell clones. These data build upon results from previous studies showing the clinical benefit of pelareorep combination therapy in PDAC and support the decision to move to a licensure-enabling study in pancreatic cancer,” said CEO Matt Coffey. “…The data we are presenting at ESMO provide a solid foundation as we advance our pancreatic cancer program through the Precision Promise Phase 3 trial in this indication.” The treatment combination has been well tolerated with no safety concerns.